Get access

Reply: Neuropsychiatric symptoms in Parkinson's disease

Authors

  • D. Aarsland,

    Corresponding author
    1. Centre for Old Age Medicine Stavanger University Hospital and Institute of Clinical Medicine University of Oslo Oslo, Norway
    • Centre for Old Age Medicine Stavanger University Hospital and Institute of Clinical Medicine University of Oslo Oslo, Norway
    Search for more papers by this author
  • L. Marsh,

    1. Neurology, Baylor College of Medicine, Houston, Texas, USA
    2. Mental Health Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    Search for more papers by this author
  • A. Schrag

    1. Reader and Honorary Consultant Neurologist, Royal Free Campus, Institute of Neurology University College London, London, England
    Search for more papers by this author

  • Potential conflict of interest: Dr. Aarsland received honorarium from GE Health, Merck Serono, Lundbeck, Novartis, and Diagenic; received research support from Lundbeck, Merck, and Serono; and serves on the advisory board for Diagenic. Dr. Marsh is supoprted by NIH grats RO1-MH069666; receives royalties from Taylor and Francis/Informa. Dr. Shrag participated in a trial by ACADIA Pharmaceuticals, Inc. that was related to this article; serves as a consultant for Servier (Institut De Recherches Internationales Servier and ADIR); serves on the advisory board for Osmotica Pharmaceuticals.

No abstract is available for this article.

Get access to the full text of this article

Ancillary